


# PRODUCT INFORMATION



## BMS 986122

Item No. 23269

**CAS Registry No.:** 313669-88-4  
**Formal Name:** 2-(3-bromo-4-methoxyphenyl)-3-[(4-chlorophenyl)sulfonyl]-thiazolidine  
**MF:** C<sub>16</sub>H<sub>15</sub>BrClNO<sub>3</sub>S<sub>2</sub>  
**FW:** 448.8  
**Purity:** ≥98%  
**UV/Vis.:** λ<sub>max</sub>: 234 nm  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

BMS 986122 is supplied as a crystalline solid. A stock solution may be made by dissolving the BMS 986122 in the solvent of choice, which should be purged with an inert gas. BMS 986122 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BMS 986122 in ethanol is approximately 2 mg/ml and approximately 10 mg/ml in DMSO and DMF.

BMS 986122 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BMS 986122 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. BMS 986122 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

BMS 986122 is a positive allosteric modulator of  $\mu$ -opioid receptors that increases  $\beta$ -arrestin recruitment stimulated by endomorphin 1 (Item No. 23280) in U2OS-OPRM1 human osteosarcoma cells expressing  $\mu$ -opioid receptors ( $EC_{50} = 3 \mu\text{M}$ ).<sup>1</sup> It potentiates endomorphin 1-induced inhibition of forskolin-stimulated adenylyl cyclase activity in CHO cells expressing human recombinant  $\mu$ -opioid receptors ( $EC_{50} = 8.9 \mu\text{M}$ ). BMS 986122 also enhances [<sup>35</sup>S]GTP $\gamma$  binding stimulated by the  $\mu$ -opioid agonist DAMGO (Item No. 21553) by 7- and 4.5-fold in C6 $\mu$  glioma cell membranes that express  $\mu$ -opioid receptors and mouse brain membranes, respectively.

### Reference

1. Burford, N.T., Clark, M.J., Wehrman, T.S., *et al.* Discovery of positive allosteric modulators and silent allosteric modulators of the  $\mu$ -opioid receptor. *Proc. Natl. Acad. Sci. U.S.A.* **110**(26), 10830-10835 (2013).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/23/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM